Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism

被引：0
|
作者：
Jacobs, Anna [1 ,2 ]
Kabra, Rajesh [3 ]
Das, Pranab [4 ]
Oliphant, Carrie S. [1 ,2 ]
机构：
[1] Methodist Univ Hosp, Dept Pharm, 1265 Union Ave, Memphis, TN 38104 USA
[2] Univ Tennessee, Coll Pharm, Dept Clin Pharm, 920 Madison Ave, Memphis, TN 38163 USA
[3] Univ Tennessee, Hlth Sci Ctr, Div Cardiol, 1325 Eastmoreland Ave Suite 460, Memphis, TN 38104 USA
[4] St Francis Cardiol Associates, 6005 Pk Ave,Suite500 B, Memphis, TN 38119 USA
来源：
FUTURE CARDIOLOGY | 2018年 / 14卷 / 01期
关键词：
apixaban; atrial fibrillation; betrixaban; dabigatran; edoxaban; review; rivaroxaban; venous thromboembolism;
D O I：
10.2217/fca-2017-0045
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Following publication of our review article 4 years ago, there has been an uptake in the use of nonvitamin K oral antagonists, also known as direct oral anticoagulants. The most recent Xa inhibitors to receive approval are edoxaban, which has been approved for use in both atrial fibrillation and venous thromboembolism prevention and betrixaban, which has been approved in the USA for extended thromboprophylaxis in the medically ill population. Additional analyses of certain types of atrial fibrillation patients have now become available. Ongoing prescriber vigilance is recommended as additional information continues to emerge with this class of medications. The purpose of this paper is to provide an update on the use of the direct oral anticoagulant agents for the prevention and treatment of thromboembolism.
引用
收藏
页码：89 / 99
页数：11
相关论文
共 50 条
  • [31] The treatment of venous thromboembolism with new oral anticoagulants
    Imberti, Davide
    ITALIAN JOURNAL OF MEDICINE, 2013, 7 : 29 - 35
  • [32] Treatment of venous thromboembolism with new oral anticoagulants
    Czihal, M.
    Hoffmann, U.
    PHLEBOLOGIE, 2011, 40 (04) : 196 - 202
  • [33] Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
    Lutsey, Pamela L.
    Walker, Rob F.
    MacLehose, Richard F.
    Alonso, Alvaro
    Adam, Terrence J.
    Zakai, Neil A.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2019, 3 (04) : 668 - 673
  • [34] Evolving use of new oral anticoagulants for treatment of venous thromboembolism
    Yeh, Calvin H.
    Gross, Peter L.
    Weitz, Jeffrey I.
    BLOOD, 2014, 124 (07) : 1020 - 1028
  • [35] Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants
    Weitz, Jeffrey I.
    Jaffer, Iqbal H.
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2016, 126 (09): : 688 - 696
  • [36] Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Patients With Active Cancer
    Ogata, Misato
    Ama, Yumi
    Ogata, Takatsugu
    Hirabatake, Masaki
    Yasui, Hisateru
    Satake, Hironaga
    IN VIVO, 2021, 35 (05): : 2747 - 2753
  • [37] Use of Direct Oral Anticoagulants in Morbidly Obese Patients
    Kido, Kazuhiko
    Lee, James C.
    Hellwig, Thaddaus
    Gulseth, Michael P.
    PHARMACOTHERAPY, 2020, 40 (01): : 72 - 83
  • [38] Direct Oral Anticoagulants and the Paradigm Shift in the Management of Venous Thromboembolism
    Lim, Hui Yin
    Nandurkar, Harshal
    Ho, Prahlad
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2018, 44 (03): : 261 - 266
  • [39] Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis
    Attard, Laura M.
    Gatt, Alex
    Bertoletti, Laurent
    Delluc, Aurelien
    Riva, Nicoletta
    VASCULAR HEALTH AND RISK MANAGEMENT, 2022, 18 : 793 - 807
  • [40] Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients
    Lee, Yun-Jeong
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 841 - 850
12345